Literature DB >> 23129079

Buprenorphine may not be as safe as you think: a pediatric fatality from unintentional exposure.

Hong K Kim1, Monica Smiddy, Robert S Hoffman, Lewis S Nelson.   

Abstract

Buprenorphine is a partial μ-opioid receptor agonist that is approved for the treatment of opioid dependency. It is generally believed to be safer than methadone because of its ceiling effect on respiratory depression. As more adults in US households use buprenorphine, an increasing number of children are being exposed. We report a fatal exposure to buprenorphine in a small child that occurred after ingestion of a caretaker's buprenorphine/naloxone. Postmortem toxicology analysis showed free serum concentrations of 52 ng/mL and 39 ng/mL for buprenorphine and norbuprenorphine, respectively. No other drugs were detected. Autopsy did not find signs of injury or trauma. The theoretical safety provided by the ceiling effect in respiratory depression from buprenorphine may not apply to children, and buprenorphine may cause dose-dependent respiratory depression.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23129079     DOI: 10.1542/peds.2012-1342

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  15 in total

Review 1.  Pharmacologic Treatment of Opioid Use Disorder: a Review of Pharmacotherapy, Adjuncts, and Toxicity.

Authors:  Michael S Toce; Peter R Chai; Michele M Burns; Edward W Boyer
Journal:  J Med Toxicol       Date:  2018-10-30

Review 2.  Efficacy and ligand bias at the μ-opioid receptor.

Authors:  E Kelly
Journal:  Br J Pharmacol       Date:  2013-08       Impact factor: 8.739

Review 3.  Buprenorphine Treatment for Adolescents and Young Adults With Opioid Use Disorders: A Narrative Review.

Authors:  Jacob T Borodovsky; Sharon Levy; Marc Fishman; Lisa A Marsch
Journal:  J Addict Med       Date:  2018 May/Jun       Impact factor: 3.702

4.  Mind the Gaps: Ontogeny of Human Brain P-gp and Its Impact on Drug Toxicity.

Authors:  Jean-Marie Nicolas; Elizabeth C M de Lange
Journal:  AAPS J       Date:  2019-05-28       Impact factor: 4.009

5.  Where Is Buprenorphine Dispensed to Treat Opioid Use Disorders? The Role of Private Offices, Opioid Treatment Programs, and Substance Abuse Treatment Facilities in Urban and Rural Counties.

Authors:  Bradley D Stein; Rosalie Liccardo Pacula; Adam J Gordon; Rachel M Burns; Douglas L Leslie; Mark J Sorbero; Sebastian Bauhoff; Todd W Mandell; Andrew W Dick
Journal:  Milbank Q       Date:  2015-09       Impact factor: 4.911

Review 6.  The New Kid on the Block--Incorporating Buprenorphine into a Medical Toxicology Practice.

Authors:  Timothy J Wiegand
Journal:  J Med Toxicol       Date:  2016-03

7.  Should the United States Government Repeal Restrictions on Buprenorphine/Naloxone Treatment?

Authors:  Kenneth Blum; Mark Gold; H Westley Clark; Kristina Dushaj; Rajendra D Badgaiyan
Journal:  Subst Use Misuse       Date:  2016-07-27       Impact factor: 2.164

8.  Pregnancy Increases Norbuprenorphine Clearance in Mice by Induction of Hepatic Glucuronidation.

Authors:  Michael Z Liao; Chunying Gao; Brian R Phillips; Naveen K Neradugomma; Lyrialle W Han; Deepak Kumar Bhatt; Bhagwat Prasad; Danny D Shen; Qingcheng Mao
Journal:  Drug Metab Dispos       Date:  2017-11-20       Impact factor: 3.922

9.  Policies related to opioid agonist therapy for opioid use disorders: The evolution of state policies from 2004 to 2013.

Authors:  Rachel M Burns; Rosalie L Pacula; Sebastian Bauhoff; Adam J Gordon; Hollie Hendrikson; Douglas L Leslie; Bradley D Stein
Journal:  Subst Abus       Date:  2015-11-13       Impact factor: 3.716

10.  Illicit buprenorphine use, interest in and access to buprenorphine treatment among syringe exchange participants.

Authors:  Aaron D Fox; Adam Chamberlain; Nancy L Sohler; Taeko Frost; Chinazo O Cunningham
Journal:  J Subst Abuse Treat       Date:  2014-08-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.